Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

EMBL Choose ambr Micro Bioreactor System for Insect Cell Culture

Published: Friday, March 08, 2013
Last Updated: Friday, March 08, 2013
Bookmark and Share
Enabling rapid production of human multi-protein complexes using baculovirus.

TAP Biosystems has announced that its advanced micro bioreactor system (ambr™) is in use at the European Molecular Biology Laboratory (EMBL) in Grenoble, France, one of the world’s leading structural biology research institutes, for rapid small scale parallel expression of human multi-protein complexes using baculovirus.

The ambr micro bioreactor system at EMBL, which was funded by the French Investissement d'Avenir Initiative is being used by EMBL scientists in the Eukaryotic Expression Facility (EEF) for culturing insect cells containing baculovirus expression systems to produce differently engineered human multi-protein complexes for crystallography studies.

These protein complexes are being assessed to determine the architecture of protein cascades and pathways that lead to human disease states.

Researchers at EMBL believe that determining these pathways will ultimately reveal pivotal points where protein complexes could be of interest in drug discovery, or as a novel class of therapeutics.

Dr Imre Berger, Group Leader, in the EEF explained: “We use baculovirus because it ensures correct expression and solubility of multi-protein complexes, as well as provides sufficient protein for crystallization. We need to study large numbers of protein complex variants and had been using shake flasks to do this.  However, this type of manual culture method is not practical for us as it is time consuming and almost impossible to evaluate many variants in parallel. So we decided last year to automate the process and when we saw the ambr system we realized that the new ambr workstation with active cooling could help to streamline multi-protein expression and accelerate our research.”

Berger added: “Our difficulty is that using baculovirus and insect cells is not like working with CHO [Chinese Hamster Ovary] cells. The cells require lower growth temperatures, and you have to add baculovirus at a specific time point for successful infection. The new ambr version overcomes these issues, allowing us to grow our insect cells at 27ºC and carry out automated virus additions. TAP’s application specialists have worked with us, showing us how to use the software to monitor cell growth during culture, and set up optimal automated infection timing. We are very happy with using ambr for baculovirus expression in insect cells. Miniaturizing baculovirus expression with the ambr is now an integral part of the ComplexINC research programme and it will have a significant impact on the pace of our work.”

Dr Barney Zoro, ambr Product Manager at TAP Biosystems concluded: "We’re delighted that this world leading research institute has chosen ambr and has, for the first time, successfully proven insect cell growth and protein expression in ambr. Their research demonstrates that ambr can facilitate small scale rapid parallel production of large sets of multi-protein complexes with baculovirus, and may potentially help uncover new targets for use in future drug discovery programmes, or even a novel class of protein therapeutics.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck and TAP Biosystems Finalists for “Best Collaboration Award”
Recognizing ambr250 as a breakthrough technology for process development.
Wednesday, October 08, 2014
TAP and Gallus Co-host Free Webinar
Explaining the benefits of using ambr15 microbioreactors for DoE.
Wednesday, October 01, 2014
New Webinars Explore Feed Strategy Challenges Using Mini Bioreactors
Detailing how to achieve consistent feeding regimes for reproducible scale-up.
Thursday, September 25, 2014
New Webinar on Mimicking Perfusion Culture Using Micro Bioreactors
Presents validation data for improving media screening and process optimization.
Friday, February 14, 2014
Scientific News
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos